Recently, it has been shown that semaglutide, a glucagon-like peptide-1 receptor agonist that reduces the risk of adverse cardiovascular events in patients with diabetes, can lessen the cardiovascular risk associated with overweight and obese patients in the absence of diabetes as well [27]. Here, GLP1R is linked to diabetes mellitus.